Novartis Exjade Clears FDA As First Oral Chelating Agent
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis receives broad indication for deferasirox for treatment of iron overload in patients over 2 years of age.
You may also be interested in...
Novartis’ Exjade Label Expansion To Get Advisory Committee Review
Indication for non-transfusion dependent thalassemia, a cluster of inherited blood disorders that cause mild anemia, will be reviewed by FDA’s Oncologic Drugs Advisory Committee Nov. 8.
ApoPharma's Ferriprox Clears FDA, But Needs Cardiac Safety Study
FDA's Oct. 14 accelerated approval of ApoPharma's second-line oral iron chelation therapy Ferriprox (deferiprone) includes a requirement that the sponsor conduct a post-marketing QT prolongation study, which the agency did not mention in background documents before the key advisory panel vote.
ApoPharma's Ferriprox Clears FDA, But Needs Cardiac Safety Study
FDA's Oct. 14 accelerated approval of ApoPharma's second-line oral iron chelation therapy Ferriprox (deferiprone) includes a requirement that the sponsor conduct a post-marketing QT prolongation study, which the agency did not mention in background documents before the key advisory panel vote.